Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Allos Therapeutics |
---|---|
Information provided by: | Allos Therapeutics |
ClinicalTrials.gov Identifier: | NCT00481871 |
This is a Phase 1/2a, non-randomized, open-label, multi-center study designed to determine the Maximum Tolerated Dose (MTD) of Pralatrexate Injection and Gemcitabine with vitamin B12 and folic acid supplementation to patients with relapsed or refractory lymphoproliferative malignancies.
Condition | Intervention | Phase |
---|---|---|
Relapsed or Refractory Lymphoproliferative Malignancies |
Drug: Pralatrexate Injection Drug: Gemcitabine hydrochloride (HCl) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Phase 1/2a Open-Label Study of Sequential Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies |
Estimated Enrollment: | 84 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | November 2010 |
Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
PDX/Gem: Experimental
Pralatrexate Injection and Gemcitabine
|
Drug: Pralatrexate Injection
Pralatrexate Injection will be administered via IV push and then followed by an infusion of Gemcitabine every other week. One cycle of treatment will be 4 weeks in duration. The total treatment duration will not exceed 12 months from first treatment.
Drug: Gemcitabine hydrochloride (HCl)
Following Pralatrexate Injection administration, Gemcitabine will be administered via IV infusion every other week. One cycle of treatment will be 4 weeks in duration. The total treatment duration will not exceed 12 months from first treatment.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis will be per the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification. Phase 1: Histologically or cytologically confirmed lymphoproliferative malignancy. Patients with either Hodgkin's disease or non-Hodgkin's lymphoma are eligible, with the exception of patients with particular B-cell lymphomas, as per exclusion criterion #1.
Phase 2a: Histologically/cytologically confirmed PTCL or B-cell lymphoma (with the exceptions per exclusion criterion #1):
Adequate hematological, hepatic, and renal function as defined by:
absolute neutrophil count (ANC) ≥ 1000/μL, platelet count ≥ 100,000/μL, total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN) (AST/ALT ≤ 5 × ULN if documented hepatic involvement with lymphoma), creatinine
≤ 1.5 mg/dL or calculated creatinine clearance ≥ 50 mL/min.
Exclusion Criteria:
Phase 1
B-cell:
PTCL:
B-cell:
Contact: Shannon Wilroy | 3034266262 | swilroy@allos.com |
Contact: Michelle Parent | 3034266262 | mparent@allos.com |
United States, California | |
Stanford University School of Medicine | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Sipra Choudhury 650-736-2563 schoudhury@stanford.edu | |
Principal Investigator: Ranjana Hira Advani, MD | |
United States, Illinois | |
University of Chicago Hospital | Recruiting |
Chicago, Illinois, United States, 60637 | |
Contact: Angela Cisneros 773-834-4075 acisnero@medicine.bsd.uchicago.edu | |
Principal Investigator: Sonali Smith, MD | |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
St. Louis, Missouri, United States, 63110 | |
Contact: Justina First 314-362-4206 jfirst@im.wustl.edu | |
Principal Investigator: Nancy Bartlett, MD | |
United States, Nebraska | |
University of Nebraska Medical Center | Recruiting |
Omaha, Nebraska, United States, 68198 | |
Contact: Maribeth Hohenstein 402-559-9053 mahohens@unmc.edu | |
Principal Investigator: Julie Vose, MD | |
United States, New York | |
Memorial Sloan-Kettering Cancer Center | Recruiting |
New York, New York, United States, 10017 | |
Contact: Hanna Weissbrot 646-227-2139 weissbrh@mskcc.org | |
Principal Investigator: Steven Horwitz, MD | |
Columbia University Medical Center | Recruiting |
New York, New York, United States, 10032 | |
Contact: Danielle Wright 212-342-3482 dw2316@columbia.edu | |
Principal Investigator: Owen O'Connor, MD, PhD | |
United States, Texas | |
Cancer Therapy & Research Center | Recruiting |
San Antonio, Texas, United States, 78229-4427 | |
Contact: Tyson DeSutter 210-450-5595 desutter@uthscsa.edu | |
Principal Investigator: Alain Mita, MD | |
United States, Washington | |
Fred Hutchinson Cancer Research Center | Recruiting |
Seattle, Washington, United States, 98109 | |
Contact: Lori Jarrett 206-667-5751 ljarrett@fhcrc.org | |
Principal Investigator: Andrei Shustov, MD, Ph.D |
Study Chair: | Steven M. Horwitz, MD | Memorial Sloan-Kettering Cancer Center |
Responsible Party: | Allos Therapeutics, Inc. ( Medical Monitor ) |
Study ID Numbers: | PDX-009 |
Study First Received: | June 1, 2007 |
Last Updated: | November 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00481871 |
Health Authority: | United States: Food and Drug Administration |
Lymphoproliferative malignancies Lymphoma Hodgkin's disease Non-Hodgkin's lymphoma PTCL T/NK-cell leukemia/lymphoma T-cell lymphoma/leukemia (HTLV 1+) Angioimmunoblastic T-cell lymphoma Blastic NK lymphoma Anaplastic large cell lymphoma T/NK-cell lymphoma |
Enteropathy-type intestinal lymphoma Hepatosplenic T-cell lymphoma Extranodal peripheral T/NK-cell lymphoma Subcutaneous panniculitis T-cell lymphoma Transformed mycosis fungoides PDX Pralatrexate Gemcitabine Gemzar Vitamin B12 Folic acid |
Sezary syndrome Lymphoma, Large B-Cell, Diffuse Hodgkin's disease Hodgkin lymphoma, adult Cutaneous T-cell lymphoma Hydroxocobalamin Immunoblastic Lymphadenopathy Lymphoma, small cleaved-cell, diffuse Aminopterin Vitamin B 12 Sezary Syndrome Mycosis Fungoides |
Intestinal Diseases Folic Acid Lymphoma, large-cell Mycoses Leukemia Lymphoma, T-Cell Lymphoma, Large-Cell, Anaplastic Anaplastic large cell lymphoma Gemcitabine Lymphoma, Non-Hodgkin Lymphoma Hodgkin Disease |
Antimetabolites Anti-Infective Agents Vitamin B Complex Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Hematinics Growth Substances Physiological Effects of Drugs Hematologic Agents |
Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Antiviral Agents Pharmacologic Actions Neoplasms Radiation-Sensitizing Agents Vitamins Therapeutic Uses Micronutrients |